PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 27915965-7 2017 The mammalian target of rapamycin inhibitors everolimus and sirolimus are preferred due to their complementary mechanisms of action and favorable nephrotoxicity profile, which have opened the way for calcineurin inhibitor reduction/withdrawal in the early posttransplant period. Sirolimus 60-69 calcineurin binding protein 1 Homo sapiens 200-221 31577671-0 2020 Randomized Sirolimus-based early calcineurin inhibitor reduction in liver transplantation: impact on renal function. Sirolimus 11-20 calcineurin binding protein 1 Homo sapiens 33-54 25582442-2 2015 This study aimed to determine whether a sirolimus (Sir)-based calcineurin inhibitor-sparing regimen is associated with a lower incidence of BK viremia. Sirolimus 40-49 calcineurin binding protein 1 Homo sapiens 62-83 27795990-1 2016 BACKGROUND: Due to lack of treatment options for early acute allograft dysfunction in the presence of tubular-interstitial injury without histological features of rejection, kidney transplant recipients are often treated with sirolimus-based therapy to prevent cumulative calcineurin inhibitor exposure and to prevent premature graft failure. Sirolimus 226-235 calcineurin binding protein 1 Homo sapiens 272-293 26677273-1 2015 BACKGROUND: Sirolimus has provided the option for calcineurin inhibitor (CNI)-free immunosuppressive therapy in both solid organ transplant (SOT) and hematopoietic stem cell transplantation (HSCT). Sirolimus 12-21 calcineurin binding protein 1 Homo sapiens 50-71 25404086-0 2015 Early withdrawal of calcineurin inhibitor from a sirolimus-based immunosuppression stabilizes fibrosis and the transforming growth factor-beta signalling pathway in kidney transplant. Sirolimus 49-58 calcineurin binding protein 1 Homo sapiens 20-41 26039212-5 2015 We targeted patients with advanced leukemia with a sirolimus-based, calcineurin inhibitor-free prophylaxis of GvHD to allow the safe infusion of unmanipulated PBSCs from haploidentical family donors (TrRaMM study, Eudract 2007-5477-54). Sirolimus 51-60 calcineurin binding protein 1 Homo sapiens 68-89 25120315-1 2014 This study was designed to evaluate whether sirolimus (SRL) conversion effectively improves renal function and histopathology in calcineurin inhibitor (CNI)-treated renal recipients with mild to moderate renal insufficiency. Sirolimus 44-53 calcineurin binding protein 1 Homo sapiens 129-150 25120315-1 2014 This study was designed to evaluate whether sirolimus (SRL) conversion effectively improves renal function and histopathology in calcineurin inhibitor (CNI)-treated renal recipients with mild to moderate renal insufficiency. Sirolimus 55-58 calcineurin binding protein 1 Homo sapiens 129-150 23813776-0 2013 Sirolimus as a calcineurin inhibitor- and renal-sparing agent: all good things come to those who wait versus spare the nephron, spoil the patient. Sirolimus 0-9 calcineurin binding protein 1 Homo sapiens 15-36 24146762-1 2013 BACKGROUND: Measures to prevent chronic calcineurin inhibitor (CNI) toxicity have included limiting exposure by switching to sirolimus (SIR). Sirolimus 125-134 calcineurin binding protein 1 Homo sapiens 40-61 23726640-0 2013 Calcineurin inhibitor conversion to rapamycin can improve graft function in living donor kidney transplantation with older donors. Sirolimus 36-45 calcineurin binding protein 1 Homo sapiens 0-21 23775875-1 2013 Mycophenolate mofetil (MMF) and sirolimus (SRL) have been used for calcineurin inhibitor (CNI) minimization to reduce nephrotoxicity following liver transplantation. Sirolimus 32-41 calcineurin binding protein 1 Homo sapiens 67-88 23775875-1 2013 Mycophenolate mofetil (MMF) and sirolimus (SRL) have been used for calcineurin inhibitor (CNI) minimization to reduce nephrotoxicity following liver transplantation. Sirolimus 43-46 calcineurin binding protein 1 Homo sapiens 67-88 23195006-0 2012 High incidence of rejection episodes and poor tolerance of sirolimus in a protocol with early steroid withdrawal and calcineurin inhibitor-free maintenance therapy in renal transplantation: experiences of a randomized prospective single-center study. Sirolimus 59-68 calcineurin binding protein 1 Homo sapiens 117-138 23223314-1 2013 BACKGROUND: Conversion to sirolimus from calcineurin inhibitor- (CNI), azathioprine- (AZA) and mycophenolate-based regimens reduces the risk of development of squamous cell carcinoma of the skin (SCC) in kidney transplant recipients (KTRs). Sirolimus 26-35 calcineurin binding protein 1 Homo sapiens 41-62 19187614-7 2009 In all the 15 patients, the calcineurin inhibitor was reduced down to one third of the original dosage after the rapamycin blood concentration became stable. Sirolimus 113-122 calcineurin binding protein 1 Homo sapiens 28-49 22357174-1 2012 BACKGROUND: The role of sirolimus (SRL) conversion in the preservation of kidney function in liver transplant (LT) recipients with calcineurin inhibitor (CNI) nephrotoxicity is unclear. Sirolimus 24-33 calcineurin binding protein 1 Homo sapiens 131-152 21836511-0 2011 De-novo calcineurin-inhibitor-free immunosuppression with sirolimus and mycophenolate mofetil after heart transplantation: 5-year results. Sirolimus 58-67 calcineurin binding protein 1 Homo sapiens 8-29 20815021-1 2010 UNLABELLED: Sirolimus is used in patients with renal insufficiency after liver transplantation (LT) and especially in those with calcineurin inhibitor (CNI)-associated nephrotoxicity. Sirolimus 12-21 calcineurin binding protein 1 Homo sapiens 129-150 20832541-10 2010 In this case report, we introduce a new morphological appearance after sirolimus therapy of isometric cytoplasmic vacuolization of the renal tubules and severe arterial hyalinosis, similar to that seen in calcineurin inhibitor induced tubular toxicity. Sirolimus 71-80 calcineurin binding protein 1 Homo sapiens 205-226 20155737-7 2010 They developed a base and final model with a genotype covariate for CL/F in patients receiving calcineurin inhibitor (CNI)-free therapy with SRL, mycophenolate mofetil and corticosteroids. Sirolimus 141-144 calcineurin binding protein 1 Homo sapiens 95-116 20061930-0 2010 Omega-3 polyunsaturated fatty acids affect sirolimus exposure in kidney transplant recipients on calcineurin inhibitor-free regimen. Sirolimus 43-52 calcineurin binding protein 1 Homo sapiens 97-118 19923086-1 2009 OBJECTIVE: To investigate the efficacy of conversion from calcineurin-inhibitor (CNI) to rapamycin in liver recipients with CNI-associated renal insufficiency. Sirolimus 89-98 calcineurin binding protein 1 Homo sapiens 124-127 19923086-6 2009 CONCLUSION: Rapamycin can be used safely as a good alternative in liver transplant recipients with CNI-related renal insufficiency. Sirolimus 12-21 calcineurin binding protein 1 Homo sapiens 99-102 21631587-1 2012 The mTOR inhibitors (ImTORs) sirolimus (SRL) and everolimus (EVR) have been increasingly used in renal transplantation as part of calcineurin inhibitor (CNI) sparing or avoidance regimens. Sirolimus 29-38 calcineurin binding protein 1 Homo sapiens 130-151 22432756-0 2012 Sirolimus conversion in liver transplant recipients with calcineurin inhibitor-induced complications: efficacy and safety. Sirolimus 0-9 calcineurin binding protein 1 Homo sapiens 57-78 22320241-1 2012 Early conversion to a calcineurin-inhibitor (CNI)-free maintenance immunosuppression with sirolimus (SRL), mycophenolate mofetil (MMF) and steroids was associated with an improved 1-year renal function as compared with a cyclosporine (CsA)-based regimen (SMART core-study). Sirolimus 90-99 calcineurin binding protein 1 Homo sapiens 22-43 21792049-0 2011 Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial. Sirolimus 66-75 calcineurin binding protein 1 Homo sapiens 83-104 21338459-0 2011 Five-year experience using sirolimus-based, calcineurin inhibitor-free immunosuppression in pediatric renal transplantation. Sirolimus 27-36 calcineurin binding protein 1 Homo sapiens 44-65 20232105-0 2010 Sirolimus-based calcineurin inhibitor withdrawal immunosuppressive regimen in kidney transplantation: a single center experience. Sirolimus 0-9 calcineurin binding protein 1 Homo sapiens 16-37 20430208-0 2010 Combined sirolimus-calcineurin inhibitor immunosuppressive therapy in simultaneous heart and kidney transplantation: a retrospective analysis of a single hospital"s experience. Sirolimus 9-18 calcineurin binding protein 1 Homo sapiens 19-40 19542890-5 2009 More substantial reduction in CNI levels is safe and effective with the introduction of sirolimus or everolimus. Sirolimus 88-97 calcineurin binding protein 1 Homo sapiens 30-33 19208105-0 2009 Conversion to sirolimus with calcineurin inhibitor elimination vs. dose minimization and renal outcome in heart and lung transplant recipients. Sirolimus 14-23 calcineurin binding protein 1 Homo sapiens 29-50 19376410-2 2009 The safety and tolerance of calcineurin inhibitor (CNI)-free sirolimus-based immunosuppressant protocols in liver transplant recipients with malignancies or high risk of tumor recurrence has been scarcely evaluated. Sirolimus 61-70 calcineurin binding protein 1 Homo sapiens 28-49 19295318-0 2009 Mycophenolate and sirolimus as calcineurin inhibitor-free immunosuppression improves renal function better than calcineurin inhibitor-reduction in late cardiac transplant recipients with chronic renal failure. Sirolimus 18-27 calcineurin binding protein 1 Homo sapiens 31-52 18657156-0 2008 Selective corticosteroid and calcineurin-inhibitor withdrawal after pancreas-kidney transplantation utilizing thymoglobulin induction and sirolimus maintenance therapy. Sirolimus 138-147 calcineurin binding protein 1 Homo sapiens 29-50 18793727-6 2008 Sirolimus is an effective maintenance immunosuppressive agent that safely allows for a reduction in calcineurin-inhibitor dosing. Sirolimus 0-9 calcineurin binding protein 1 Homo sapiens 100-121 18930138-8 2008 Minimization of calcineurin inhibitor exposure may be achieved with concurrent use of the more potent anti-proliferative agents mycophenolate mofetil and sirolimus. Sirolimus 154-163 calcineurin binding protein 1 Homo sapiens 16-37 19100499-0 2008 Severe sirolimus-related inflammatory state anemia in an HIV+ liver transplant patient with calcineurin inhibitor renal insufficiency: a case report. Sirolimus 7-16 calcineurin binding protein 1 Homo sapiens 92-113 17690032-0 2007 Sirolimus as primary immunosuppressant for calcineurin inhibitor-related renal insufficiency after liver transplantation. Sirolimus 0-9 calcineurin binding protein 1 Homo sapiens 43-64 18005087-1 2008 The aim was to evaluate long-term graft survival and function after conversion to sirolimus (SRL) for chronic calcineurin inhibitor (CNI) toxicity and the predictive value of baseline proteinuria. Sirolimus 82-91 calcineurin binding protein 1 Homo sapiens 110-131 17919619-0 2007 Sirolimus-based immunosuppression after cardiac transplantation: predictors of recovery from calcineurin inhibitor-induced renal dysfunction. Sirolimus 0-9 calcineurin binding protein 1 Homo sapiens 93-114 18562571-2 2008 Calcineurin inhibitor (CNI) withdrawal from a sirolimus-based immunosuppressive regimen may maximize the likelihood of long-term graft and patient survival by minimizing CNI-associated nephrotoxicity. Sirolimus 46-55 calcineurin binding protein 1 Homo sapiens 0-21 18562571-2 2008 Calcineurin inhibitor (CNI) withdrawal from a sirolimus-based immunosuppressive regimen may maximize the likelihood of long-term graft and patient survival by minimizing CNI-associated nephrotoxicity. Sirolimus 46-55 calcineurin binding protein 1 Homo sapiens 23-26 18562571-2 2008 Calcineurin inhibitor (CNI) withdrawal from a sirolimus-based immunosuppressive regimen may maximize the likelihood of long-term graft and patient survival by minimizing CNI-associated nephrotoxicity. Sirolimus 46-55 calcineurin binding protein 1 Homo sapiens 170-173 18562571-3 2008 In this study, a lifetime Markov model was created to compare the cost-effectiveness of a sirolimus-based CNI withdrawal regimen (sirolimus plus steroids) with other common CNI-containing regimens in adult de novo renal transplantation patients. Sirolimus 90-99 calcineurin binding protein 1 Homo sapiens 106-109 18562571-3 2008 In this study, a lifetime Markov model was created to compare the cost-effectiveness of a sirolimus-based CNI withdrawal regimen (sirolimus plus steroids) with other common CNI-containing regimens in adult de novo renal transplantation patients. Sirolimus 130-139 calcineurin binding protein 1 Homo sapiens 106-109 18562571-6 2008 The model suggests that treatment with sirolimus plus steroids is more efficacious and less costly than regimens consisting of a CNI, mycophenolate mofetil, and steroids; therefore, CNI withdrawal not only shows potential for long-term clinical benefits but also is expected to be cost-saving over a patient"s life compared with the most commonly prescribed CNI-containing regimens. Sirolimus 39-48 calcineurin binding protein 1 Homo sapiens 182-185 18562571-6 2008 The model suggests that treatment with sirolimus plus steroids is more efficacious and less costly than regimens consisting of a CNI, mycophenolate mofetil, and steroids; therefore, CNI withdrawal not only shows potential for long-term clinical benefits but also is expected to be cost-saving over a patient"s life compared with the most commonly prescribed CNI-containing regimens. Sirolimus 39-48 calcineurin binding protein 1 Homo sapiens 182-185 18217899-7 2008 RESULTS: Calcineurin inhibitor minimization using mycophenolate mofetil or sirolimus may be associated with a modest increase in creatinine clearance (CrCl) and a decrease in serum creatinine (SCr) in the short term. Sirolimus 75-84 calcineurin binding protein 1 Homo sapiens 9-30 17284993-4 2007 Novel immunosuppressive regimens including mycophenolate mofetil and/or rapamycin that lack nephrotoxicity promise new therapeutic strategies with the efficacy of calcineurin inhibitor-based combinations. Sirolimus 72-81 calcineurin binding protein 1 Homo sapiens 163-184 17616271-4 2007 The approval of the new immunosuppressive agents: rabbit antithymocyte globulin, basiliximab, daclizumab, tacrolimus, mycophenolate, and sirolimus, also has facilitated the development of steroid- and calcineurin inhibitor-sparing regimens in kidney transplantation. Sirolimus 137-146 calcineurin binding protein 1 Homo sapiens 201-222 17401488-10 2007 Further development of effective calcineurin inhibitor-free regimens should exclude patients of black ethnicity and may need full-induction therapy, perhaps with depleting agents, and concentration-controlled use of sirolimus and MMF. Sirolimus 216-225 calcineurin binding protein 1 Homo sapiens 33-54 16871248-0 2006 The place of sirolimus in kidney transplantation: can we reduce calcineurin inhibitor renal toxicity? Sirolimus 13-22 calcineurin binding protein 1 Homo sapiens 64-85 17175304-1 2006 This study compared early postoperative complications in kidney transplant recipients treated with either a sirolimus-based calcineurin inhibitor (CNI)-free regimen or a tacrolimus-based steroid-free regimen. Sirolimus 108-117 calcineurin binding protein 1 Homo sapiens 124-145 17096757-0 2006 Sirolimus pharmacokinetics in pediatric renal transplant recipients receiving calcineurin inhibitor co-therapy. Sirolimus 0-9 calcineurin binding protein 1 Homo sapiens 78-99 17096757-1 2006 We have previously reported sirolimus (SRL) pharmacokinetics (PK) in pediatric renal transplant recipients on a calcineurin inhibitor (CNI)-free protocol. Sirolimus 28-37 calcineurin binding protein 1 Homo sapiens 112-133 16954170-1 2006 BACKGROUND: Conversion from calcineurin inhibitor to sirolimus, rapamycin has become an option in patients with chronic allograft dysfunction (CAD). Sirolimus 64-73 calcineurin binding protein 1 Homo sapiens 28-49 16906035-1 2006 BACKGROUND: Calcineurin inhibitor(CNI)-free protocols using sirolimus (SRL) in kidney transplantation have proven effective, although reports have linked SRL to proteinuria. Sirolimus 60-69 calcineurin binding protein 1 Homo sapiens 12-33 16364861-0 2005 Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity. Sirolimus 0-9 calcineurin binding protein 1 Homo sapiens 76-97 16740435-13 2006 CONCLUSIONS: Monitored sirolimus conversion with sharp withdrawal of calcineurin inhibitor is an alternative for patients with deteriorating renal function and chronic allograft nephropathy. Sirolimus 23-32 calcineurin binding protein 1 Homo sapiens 69-90 16797286-12 2006 CONCLUSION: Conversion from calcineurin inhibitor therapy to sirolimus in patients more than 1 year after transplantation with impaired organ function is feasible, safe, and associated with a trend toward improved renal function. Sirolimus 61-70 calcineurin binding protein 1 Homo sapiens 28-49 16534470-10 2006 CONCLUSIONS: Conversion to a sirolimus-based immunosuppression regimen associated with MMF allowed striking renal function recovery in heart transplant recipients with calcineurin inhibitor-induced renal impairment at midterm follow-up. Sirolimus 29-38 calcineurin binding protein 1 Homo sapiens 168-189 16303023-0 2005 Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: a systematic review of randomized trials. Sirolimus 38-47 calcineurin binding protein 1 Homo sapiens 0-21 16237714-8 2005 The use of calcineurin inhibitor (CNI)-based immunosuppression is an important factor in the development of chronic kidney disease, and the use of mycophenolic acid- or sirolimus-based immunosuppression with reduced-dose CNI may be of benefit. Sirolimus 169-178 calcineurin binding protein 1 Homo sapiens 221-224 16162204-0 2005 Comparison of sirolimus with low-dose tacrolimus versus sirolimus-based calcineurin inhibitor-free regimen in live donor renal transplantation. Sirolimus 56-65 calcineurin binding protein 1 Homo sapiens 72-93 16678029-5 2006 With the introduction of rapamycin, the patients were given a lower dose of calcineurin inhibitors, and the calcineurin inhibitor was discontinued in 5 patients. Sirolimus 25-34 calcineurin binding protein 1 Homo sapiens 76-97 16678029-13 2006 CONCLUSIONS: The introduction of rapamycin to the immunosuppressive regimen of patients taking calcineurin inhibitors, with a concomitant reduction of the calcineurin inhibitor dose, may improve renal function within 30 days, without a significant increase in rejection. Sirolimus 33-42 calcineurin binding protein 1 Homo sapiens 95-116 16421477-9 2006 Maintenance immunosuppression with the combination of a calcineurin inhibitor and sirolimus carried a significantly higher risk of TMA than a calcineurin inhibitor alone. Sirolimus 82-91 calcineurin binding protein 1 Homo sapiens 142-163 17048977-12 2006 CONCLUSION: This study presents an accurate population pharmacokinetic model showing the significant influence of the CYP3A5*1/*3 polymorphism on sirolimus apparent oral clearance, and a Bayesian estimator accurately predicting sirolimus pharmacokinetics in patients co-administered mycophenolate mofetil, but no calcineurin inhibitor. Sirolimus 146-155 calcineurin binding protein 1 Homo sapiens 313-334 17048977-12 2006 CONCLUSION: This study presents an accurate population pharmacokinetic model showing the significant influence of the CYP3A5*1/*3 polymorphism on sirolimus apparent oral clearance, and a Bayesian estimator accurately predicting sirolimus pharmacokinetics in patients co-administered mycophenolate mofetil, but no calcineurin inhibitor. Sirolimus 228-237 calcineurin binding protein 1 Homo sapiens 313-334 15849545-0 2005 The effect of 2-gram versus 1-gram concentration controlled mycophenolate mofetil on renal transplant outcomes using sirolimus-based calcineurin inhibitor drug-free immunosuppression. Sirolimus 117-126 calcineurin binding protein 1 Homo sapiens 133-154 15919502-0 2005 Successful conversion to rapamycin for calcineurin inhibitor-related neurotoxicity following liver transplantation. Sirolimus 25-34 calcineurin binding protein 1 Homo sapiens 39-60 15943635-0 2005 Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: a systematic review of randomized trials. Sirolimus 38-47 calcineurin binding protein 1 Homo sapiens 0-21 15943635-2 2005 We conducted a systematic review of randomized trials that involved CNI withdrawal from a sirolimus-based immunosuppressive regimen. Sirolimus 90-99 calcineurin binding protein 1 Homo sapiens 68-71 15943635-4 2005 CNI withdrawal from sirolimus-based therapy, was associated with an increased risk of acute rejection (risk difference, 6%; 95% CI 2-10%, p = 0.002) but a higher creatinine clearance (mean difference, 7.49 mL/min; 95% CI 5.08-9.89 mL/min, p < 0.00001) at 1 year compared to continued CNI and sirolimus therapy. Sirolimus 20-29 calcineurin binding protein 1 Homo sapiens 0-3 15943635-4 2005 CNI withdrawal from sirolimus-based therapy, was associated with an increased risk of acute rejection (risk difference, 6%; 95% CI 2-10%, p = 0.002) but a higher creatinine clearance (mean difference, 7.49 mL/min; 95% CI 5.08-9.89 mL/min, p < 0.00001) at 1 year compared to continued CNI and sirolimus therapy. Sirolimus 20-29 calcineurin binding protein 1 Homo sapiens 287-290 15943635-4 2005 CNI withdrawal from sirolimus-based therapy, was associated with an increased risk of acute rejection (risk difference, 6%; 95% CI 2-10%, p = 0.002) but a higher creatinine clearance (mean difference, 7.49 mL/min; 95% CI 5.08-9.89 mL/min, p < 0.00001) at 1 year compared to continued CNI and sirolimus therapy. Sirolimus 295-304 calcineurin binding protein 1 Homo sapiens 0-3 15943635-7 2005 CNI withdrawal from sirolimus-based therapy is associated with an increased risk of acute rejection in the short term with a significant improvement in renal function and a reduction in hypertension. Sirolimus 20-29 calcineurin binding protein 1 Homo sapiens 0-3 15760408-8 2005 Complete abandonment of calcineurin inhibitor therapy by de novo use of the combination sirolimus/mycophenolate mofetil resulted in low rejection rate and avoidance of renal impairment, but should not be used without further evaluation of potential complications in a lager setting. Sirolimus 88-97 calcineurin binding protein 1 Homo sapiens 24-45 15631539-14 2005 Multicentre and single-centre reports have demonstrated that both calcineurin inhibitor withdrawal and avoidance were possible when sirolimus was used in a concentration-controlled fashion, with low-dose corticosteroids and MMF. Sirolimus 132-141 calcineurin binding protein 1 Homo sapiens 66-87 15256816-0 2004 Sirolimus dosage during and after conversion from calcineurin inhibitor therapy to sirolimus in chronic kidney transplant patients. Sirolimus 0-9 calcineurin binding protein 1 Homo sapiens 50-71 15621119-0 2004 Sirolimus addition is beneficial for renal allograft dysfunction due to simultaneous acute rejection episode and calcineurin inhibitor nephrotoxicity. Sirolimus 0-9 calcineurin binding protein 1 Homo sapiens 113-134 15366440-0 2004 Sirolimus and mycophenolate mofetil as calcineurin inhibitor-free immunosuppression in a cardiac transplant patient with chronic renal failure. Sirolimus 0-9 calcineurin binding protein 1 Homo sapiens 39-60 15114090-0 2004 Comparison of sirolimus-based calcineurin inhibitor-sparing and calcineurin inhibitor-free regimens in cadaveric renal transplantation. Sirolimus 14-23 calcineurin binding protein 1 Homo sapiens 30-51 14762856-5 2004 In the sirolimus group, perioperative steroids were reduced, and calcineurin inhibitor initiation was delayed. Sirolimus 7-16 calcineurin binding protein 1 Homo sapiens 65-86 15367229-2 2004 However, sirolimus can potentiate calcineurin inhibitor (CNI) nephrotoxicity by some still uncertain mechanisms. Sirolimus 9-18 calcineurin binding protein 1 Homo sapiens 34-55 12962787-10 2003 Sirolimus seems to be a promising alternative for the treatment of renal transplant patients who develop calcineurin inhibitor-induced DnHUS. Sirolimus 0-9 calcineurin binding protein 1 Homo sapiens 105-126 14697970-0 2003 Sirolimus therapy in orthotopic liver transplant recipients with calcineurin inhibitor related chronic renal insufficiency. Sirolimus 0-9 calcineurin binding protein 1 Homo sapiens 65-86 14697970-2 2003 Our clinical experience has revealed sirolimus to be an effective agent in treating renal insufficiency related to calcineurin inhibitor toxicity. Sirolimus 37-46 calcineurin binding protein 1 Homo sapiens 115-136 14612104-0 2003 Low-dose sirolimus in combination with mycophenolate in calcineurin inhibitor elimination: the Kuwaiti experience. Sirolimus 9-18 calcineurin binding protein 1 Homo sapiens 56-77 12493414-0 2002 Sirolimus rescue treatment in calcineurin-inhibitor nephrotoxicity after kidney transplantation. Sirolimus 0-9 calcineurin binding protein 1 Homo sapiens 30-51 11750386-0 2001 Conversion to rapamycin in renal allograft recipients with biopsy-proven calcineurin inhibitor-induced nephrotoxicity. Sirolimus 14-23 calcineurin binding protein 1 Homo sapiens 73-94 11583938-3 2001 A strategy that may result in a more benign immunologic course with a substantially beneficial effect on renal function is to administer sirolimus and a calcineurin inhibitor early after transplantation, thereby promoting immunologic adaptation, and then to withdraw the calcineurin inhibitor at some point after transplantation to prevent nephrotoxicity. Sirolimus 137-146 calcineurin binding protein 1 Homo sapiens 271-292 11127307-0 2000 A calcineurin inhibitor-sparing regimen with sirolimus, mycophenolate mofetil, and anti-CD25 mAb provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft function. Sirolimus 45-54 calcineurin binding protein 1 Homo sapiens 2-23 12234280-3 2002 In two children who underwent living donor kidney transplantation for atypical HUS, we pre-emptively employed sirolimus in a calcineurin inhibitor-free immunosuppression regimen. Sirolimus 110-119 calcineurin binding protein 1 Homo sapiens 125-146 12372044-0 2002 Calcineurin inhibitor-induced chronic nephrotoxicity in liver transplant patients is reversible using rapamycin as the primary immunosuppressive agent. Sirolimus 102-111 calcineurin binding protein 1 Homo sapiens 0-21 12372044-1 2002 The purpose of this study was to determine whether calcineurin inhibitor (CNI)-induced chronic nephrotoxicity in liver transplant patients is reversible by replacement of the CNI with rapamycin as the primary immunosuppressive agent. Sirolimus 184-193 calcineurin binding protein 1 Homo sapiens 51-72 12372044-1 2002 The purpose of this study was to determine whether calcineurin inhibitor (CNI)-induced chronic nephrotoxicity in liver transplant patients is reversible by replacement of the CNI with rapamycin as the primary immunosuppressive agent. Sirolimus 184-193 calcineurin binding protein 1 Homo sapiens 74-77 12372044-11 2002 One patient with chronic nephrolithiasis as a contributing factor to his renal dysfunction has progressed to dialysis dependence despite conversion to rapamycin following exposure to a CNI for 24 months. Sirolimus 151-160 calcineurin binding protein 1 Homo sapiens 185-188 12372044-15 2002 Rapamycin is an effective replacement agent as primary immunosuppressive therapy following withdrawal of CNIs in liver transplant patients with CNI-induced chronic nephrotoxicity. Sirolimus 0-9 calcineurin binding protein 1 Homo sapiens 105-108 35282339-6 2022 Our group has also demonstrated that conversion from calcineurin inhibitor to the mammalian target of rapamycin (mTOR) inhibitor, sirolimus, as a primary immunosuppression was associated with a decreased risk of PTLD following HT. Sirolimus 130-139 calcineurin binding protein 1 Homo sapiens 53-74